Our Mission

Agendia is committed to improving the quality of life for cancer patients through molecular diagnostics, one patient at a time

A growing business

We were founded in 2003 as a spin-off from the Netherlands Cancer Institute / Antoni van Leeuwenhoek Hospital in Amsterdam, for the purpose of commercializing molecular diagnostics using DNA microarray technology for cancer diagnosis and drug development. In 2004, we launched our first test, the MammaPrint® 70-gene breast cancer recurrence assay in Europe.  In 2007, MammaPrint became the first IVDMIA to obtain 510(k) clearance from the FDA, and after receipt of the regulatory clearance, was made commercially available in the United States in 2008. Since the initial 510(k) clearance, MammaPrint has received four additional FDA clearances.  Our sixth and most recent 510(k) clearance for MammaPrint® FFPE was received in February 2015.

In 2009, a significant landmark in our commercial development was our positive local coverage determination by the Medicare carrier in California which processes all of our Medicare reimbursement claims.

MammaPrint is the fastest growing breast cancer recurrence assay and has helped over 48,000 patients from almost 50 countries.